Login / Signup

Two-year persistence with teriparatide improved significantly after introduction of an educational and motivational support program.

M A van MarenCaroline E WyersJ H M DriessenJ V VisserF de VriesK van de WijdevenS GeversW F LemsM H Emmelot-VonkJ P W van den Bergh
Published in: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2019)
The introduction of the EMSP has demonstrated to improve the persistence with TPTD, resulting in 78% of the patients being persistent with TPTD during the 2-year treatment period.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • patient reported outcomes
  • bone mineral density